The useful question is how much reliable biological information a workflow delivers. Colour count alone cannot answer it.
Original CFCM report: 28 August 2026. Expanded for pre-launch review; this is not a retrospective web-publication date.
Primary evidence
Peer-reviewed methods: Rietdijk MH, Kuhnen LC, van den Braber M, Paul AGA, Pascutti MF and García-Vallejo JJ. Comprehensive immune profiling of human peripheral blood mononuclear cells using two complementary spectral flow cytometry panels encompassing 60 unique markers. Frontiers in Immunology, published 1 September 2026. DOI: 10.3389/fimmu.2026.1894779. This published version postdates the original August report and is used in this expanded review.
PAPER · Methods study
Comprehensive immune profiling of human peripheral blood mononuclear cells using two complementary spectral flow cytometry panels encompassing 60 unique markers
Rietdijk et al. · Frontiers in Immunology · 2026
DOI: 10.3389/fimmu.2026.1894779
CFCM summary. Two complementary panels combine lineage and functional markers for broad PBMC profiling.
Limit. The published workflow is instrument- and application-specific; it does not validate clinical MRD performance.
Two complementary panels on a five-laser Aurora cover 60 unique markers and resolve more than 50 populations. The materials section lists eight healthy donors, seven glioblastoma, six chronic-inflammation and six COVID-19 samples. Alberta Paul has a Cytek affiliation. The work demonstrates a practical multi-panel immunomonitoring strategy, not a clinical comparison proving that two tubes always outperform one.
Evidence boundary
The title is a CFCM hypothesis about priorities, not a measured decline in high-parameter cytometry. The study does not establish clinical MRD performance, reduced cost in routine diagnostics or universal transfer across instruments. Splitting markers also loses direct same-cell co-expression information between tubes; a biological question requiring that information may favour a single panel.
What changes in practice
CFCM evaluation framework: first list the populations and co-expression relationships needed for the decision. Identify which must be observed in the same cells. Compare candidate layouts using the specimen volume available, dim-marker separation, repeatability, controls, analysis time and failure rate. Include difficult specimens rather than judging only visually attractive healthy-donor plots. Define acceptance criteria before comparing alternatives.
CFCM view
More markers remain useful when they resolve a real question. The stronger competitive claim is a workflow that preserves its meaning across batches, operators and intended samples. A laboratory should be able to explain the role of each added marker and the consequence of losing it. The race may change its scoring system; the evidence does not say that high-colour panels are obsolete.
Professional background includes Sysmex, Newcastle University and the NHS. CFCM is Juan Manuel Ojeda's independent editorial project and represents the author alone. Manufacturer references do not imply endorsement. Relevant professional or financial relationships are disclosed alongside the affected coverage.
Expanded web version and source-check pass: 19 September 2026. This was not independent scientific review. The original-report date is preserved separately above.